Options
Ph.D. Program for Translational Medicine / 轉譯醫學博士學位學程
Loading...
Country
Taiwan
Description
Given the significant shortage of talent in the field of translational medicine research in Taiwan, particularly of physician-scientists with advantageous qualifications to conduct such research, our university has collaborated with Academia Sinica to jointly establish a PhD program in translational medicine. Through the joint guidance of both basic and clinical faculty, the program helps students understand the concepts, ethics, regulations, and research methods of translational medicine. The program aims to address clinical problems through modern and innovative translational medicine research methods, exploring gene-related diseases and their molecular pathological mechanisms, from basic research to clinical trials—essentially from the laboratory to the patient. The findings based on these studies can lead to the development of innovative diagnostics or targeted therapies, thereby overcoming current bottlenecks in medical development.
This program was approved by the Ministry of Education in June 2011 and officially began enrolling students in August 2012. It is jointly managed by Academia Sinica and seven medical universities nationwide (including National Taiwan University and Kaohsiung Medical University in the 100th academic year; National Yang-Ming University, Taipei Medical University, China Medical University in the 101st academic year; and Tzu Chi University and National Defense Medical Center in the 103rd academic year). The program operates in the same manner across all seven universities, with both the medical universities and Academia Sinica appointing a joint chief convenor. An "Executive Committee" is established under which there are three subcommittees: "Admissions Committee," "Academic Affairs Committee," and "Student Affairs Committee," with members from both institutions serving on these committees. Advisory committee members are appointed as needed. The program also includes full-time faculty, joint appointments of internal and external scholars, several Academia Sinica academicians, distinguished professors, and guest professors with practical experience in the biotech industry to participate in teaching and guiding students.
This program was approved by the Ministry of Education in June 2011 and officially began enrolling students in August 2012. It is jointly managed by Academia Sinica and seven medical universities nationwide (including National Taiwan University and Kaohsiung Medical University in the 100th academic year; National Yang-Ming University, Taipei Medical University, China Medical University in the 101st academic year; and Tzu Chi University and National Defense Medical Center in the 103rd academic year). The program operates in the same manner across all seven universities, with both the medical universities and Academia Sinica appointing a joint chief convenor. An "Executive Committee" is established under which there are three subcommittees: "Admissions Committee," "Academic Affairs Committee," and "Student Affairs Committee," with members from both institutions serving on these committees. Advisory committee members are appointed as needed. The program also includes full-time faculty, joint appointments of internal and external scholars, several Academia Sinica academicians, distinguished professors, and guest professors with practical experience in the biotech industry to participate in teaching and guiding students.